Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy

(2021) Martin S. Maron et al.   CIRCULATION

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

(2021) Chihyuan Chuang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy

(2021) Anne M. Dybro et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM

(2020) Perry M Elliott   CARDIOVASCULAR RESEARCH

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Iacopo Olivotto et al.   LANCET

Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR Substudy Analysis

(2020) Sara Saberi et al.   CIRCULATION

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

(2020) Steve R. Ommen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical Course and Management of Hypertrophic Cardiomyopathy

(2018) Barry J. Maron   NEW ENGLAND JOURNAL OF MEDICINE

How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality

(2016) Barry J. Maron et al.   JAMA Cardiology

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

(2014)   EUROPEAN HEART JOURNAL

Treatment of Obstructive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy With β-Blockade or Verapamil

(2013) Mark V. Sherrid et al.   Circulation-Heart Failure